The investigation, spearheaded by attorney Juan Monteverde, targets the mechanics of the deal between the NASDAQ-listed Boundless Bio and Serapha Bio. With the firm positioning itself as a specialist in securities litigation, the inquiry aims to determine if the terms of the merger favor stakeholders or undervalue the interests of those holding common stock.

Shareholders currently navigating the transition are being invited to review the deal's structure through the firm’s legal portal. Monteverde & Associates, which operates out of the Empire State Building, emphasizes that these consultations carry no cost or obligation for investors seeking to understand their rights amid the corporate reorganization.